Samsung Bioepis Secures FDA Approval for Pyzchiva, a Biosimilar to Stelara, Extending Treatment Options for Multiple Inflammatory Conditions
Samsung Bioepis Receives FDA Approval for Pyzchiva, a Biosimilar to Stelara, for Multiple Inflammatory Conditions Samsung Bioepis Co., Ltd. has achieved a significant milestone with the US Food and Drug Administration (FDA) granting approval to its Biologics License Application (BLA) for Pyzchiva (ustekinumab-ttwe). Pyzchiva is now approved for both subcutaneous injection and intravenous infusion, serving … Read more